- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®
eptinezumab is an approved drug (FDA (2020), EMA (2022))
Compound class: Antibody
Comment: Eptinezumab is a humanized IgG1 anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine . It was developed by Lundbeck and their subsidiary Alder Biopharmaceuticals (Alderbio). The INN record for eptinezumab indicates that it binds to CALCA (α-CGRP) and CALCB (β-CGRP). Peptide sequence alignment using NCBI BLAST Protein reveals 100% matches with sequences claimed in Alderbio's patent WO2012162257A2, and distinguish eptinezumab as the monoclonal referred to as Ab5 in the patent document.
CGRP plays an important role in migraine pathophysiology , and both the CGRP peptide and its receptor (CGRPR) are targets of anti-migraine therapeutics [1,4-5]. Eptinezumab is the fourth anti-CGRP pathway monoclonal to reach the clinic: the others are erenumab (anti-CGRPR), galcanezumab (anti-CALCA/B) and fremanezumab (anti-CALCA/B). These antibodies are used as alternatives to CGRPR antagonists such as ubrogepant (FDA approved in 2019).
|Approved drug?||Yes (FDA (2020), EMA (2022))|
|International Nonproprietary Names|
|ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®|
|GtoPdb PubChem SID||404859141|
|Search PubMed clinical trials||eptinezumab|
|Search PubMed titles||eptinezumab|
|Search PubMed titles/abstracts||eptinezumab|